Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129 JPY | +4.03% | -3.73% | -39.15% |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 5,586 | - | - |
Enterprise Value (EV) 1 | 5,586 | 5,586 | 5,586 |
P/E ratio | -6.56 x | -6.36 x | -6.17 x |
Yield | - | - | - |
Capitalization / Revenue | 17.5 x | 17.5 x | 17.5 x |
EV / Revenue | 17.5 x | 17.5 x | 17.5 x |
EV / EBITDA | -6.57 x | -6.38 x | -6.18 x |
EV / FCF | - | - | - |
FCF Yield | - | - | - |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 43,302 | - | - |
Reference price 2 | 129.0 | 129.0 | 129.0 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | 625.8 | 319 | 319 | 319 |
EBITDA 1 | - | -850 | -876 | -904 |
EBIT 1 | - | -849.5 | -876.2 | -904 |
Operating Margin | - | -266.3% | -274.67% | -283.39% |
Earnings before Tax (EBT) 1 | - | -850 | -876 | -904 |
Net income 1 | -386.6 | -851 | -877 | -905 |
Net margin | -61.78% | -266.77% | -274.92% | -283.7% |
EPS 2 | - | -19.65 | -20.27 | -20.90 |
Free Cash Flow | - | - | - | - |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 3/13/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: |
---|
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/13/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-39.15% | 34.08M | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- 4893 Stock
- Financials Noile-Immune Biotech Inc.